Effect of probiotic supplementation on lipoprotein-associated phospholipase A2 in type 2 diabetic patients

Tehran University of Medical Sciences0 个研究点目标入组 68 人开始时间: 待定最近更新: 2022年3月8日

适应症

试验速览

暂无简介。

•Age between50 - 65 years
•Type 2 diabetic patients that diagnosed at least 2 years ago.
•BMI between 25 – 34.9 kg/m2
•The patient or caregiver understands the objectives of the study and agrees to follow the necessary rules throughout the study.

•Irregular diet and unstable body weight (body-weight change > 5% within 3 months before screening)
•Type 1 diabetes or non-diabetic patients
•History of Cardiovascular disease, Hypertension, heart attack, angina pectoris, cerebrovascular disease, stroke, Thyroid disease, and other chronic diseases and transmitted diseases in the past year.
•Dietary supplementation of probiotics within 6 months before screening
•Pregnancy or breast-feeding
•Use of smoke and alcohol during the last three months prior the study.
•Consumption of medication that affects body weight, energy expenditure, glucose control, or antibiotic treatment within 3 months before screening.
•using any drug other than metformin, sulfonylurea, statins, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and aspirin at doses of 80?mg or less
•Changing in medications received in the previous three months.
•Having any allergic reaction after our intervention.
•Participants who consume less than 80% of the supplement.
•Further exclusion criteria are acute or chronic infections, liver disease, kidney disease, gastrointestinal disease, or any other acute or chronic disease requiring treatment.

发起方